ERNA - Eterna Therapeutics Inc.
NASDAQ
->
Healthcare
->
Biotechnology
San Diego,
United States
Type: Equity
ERNA price evolution
ERNA
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $4.26 | $2.59 | $5.12 | $7.58 |
| Short term investments | ||||
| Net receivables | $0.19 | $0.23 | $0.35 | $0.42 |
| Inventory | ||||
| Total current assets | $4.73 | $3.58 | $6.16 | $9.6 |
| Long term investments | ||||
| Property, plant & equipment | $0.82 | $36.64 | $37.23 | $33.27 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $7.72 | $46.49 | $49.66 | $49.13 |
| Current liabilities | ||||
| Accounts payable | $2.19 | $2.19 | $2.06 | $1.07 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $9.95 | $9.6 | $7.77 | $6.57 |
| Long term debt | $32.04 | $8.89 | $8.01 | $6.77 |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $53.11 | $55.01 | $53.07 | $46.9 |
| Shareholders' equity | ||||
| Retained earnings | -$225.77 | -$199.16 | -$193.63 | -$186.98 |
| Other shareholder equity | ||||
| Total shareholder equity | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $7.58 | $11.45 | $16.99 | |
| Short term investments | ||||
| Net receivables | $0.42 | $0.95 | $0.68 | $0.12 |
| Inventory | ||||
| Total current assets | $9.6 | $13.68 | $18.77 | $1.72 |
| Long term investments | ||||
| Property, plant & equipment | $33.27 | $1.33 | $4.24 | $0.54 |
| Goodwill & intangible assets | ||||
| Total noncurrent assets | ||||
| Total investments | ||||
| Total assets | $49.13 | $22.28 | $31.53 | $3.75 |
| Current liabilities | ||||
| Accounts payable | $1.07 | $1.62 | $1.76 | $0.27 |
| Deferred revenue | ||||
| Short long term debt | ||||
| Total current liabilities | $6.57 | $7.65 | $3.68 | $2.36 |
| Long term debt | $6.77 | $1.21 | $0.53 | |
| Total noncurrent liabilities | ||||
| Total debt | ||||
| Total liabilities | $46.9 | $10.17 | $6.02 | $2.89 |
| Shareholders' equity | ||||
| Retained earnings | -$186.98 | -$165.3 | -$140.7 | -$135.89 |
| Other shareholder equity | $0.25 | |||
| Total shareholder equity | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.49 | $0.05 | $0.05 | $0.02 |
| Cost of revenue | ||||
| Gross Profit | $0.55 | -$0.05 | -$0.01 | -$0.05 |
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $4.38 | $4.88 | $5.77 | $5.72 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | $0.01 | $0 | $0 | -$0 |
| Interest expense | -$1.69 | -$0.8 | -$0.79 | -$0.48 |
| Net income | ||||
| Net income | -$26.6 | -$5.54 | -$6.65 | -$6.16 |
| Income (for common shares) | ||||
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $0.07 | $5.8 | ||
| Cost of revenue | ||||
| Gross Profit | -$0.17 | $2.89 | ||
| Operating activities | ||||
| Research & development | ||||
| Selling, general & administrative | ||||
| Total operating expenses | $20.51 | $27.23 | $27.43 | $8.29 |
| Operating income | ||||
| Income from continuing operations | ||||
| EBIT | ||||
| Income tax expense | -$0 | $0.05 | $0.06 | -$0.01 |
| Interest expense | -$0.54 | -$0.97 | -$0.07 | -$0.14 |
| Net income | ||||
| Net income | -$21.68 | -$24.6 | -$122.56 | -$4.43 |
| Income (for common shares) | ||||
| (in millions $) | 30 Oct 2024 | 30 Jul 2024 | 1 May 2024 | 31 Jan 2024 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.36 | -$0.35 | -$0.1 | -$0.02 |
| Financing activities | ||||
| Dividends paid | -$0.01 | -$0.01 | -$0.02 | |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $5.25 | $1.36 | $1.39 | $16.56 |
| Effect of exchange rate | ||||
| Change in cash and equivalents | -$7.41 | -$4.99 | -$2.46 | -$3.87 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Jan 2022 | 31 Jan 2021 |
|---|---|---|---|---|
| Net income | ||||
| Operating activities | ||||
| Depreciation | ||||
| Business acquisitions & disposals | ||||
| Stock-based compensation | ||||
| Total cash flows from operations | ||||
| Investing activities | ||||
| Capital expenditures | ||||
| Investments | ||||
| Total cash flows from investing | -$0.02 | -$0.05 | -$22.74 | $0.96 |
| Financing activities | ||||
| Dividends paid | -$0.02 | -$0.02 | -$0.01 | -$0.02 |
| Sale and purchase of stock | ||||
| Net borrowings | ||||
| Total cash flows from financing | $16.56 | $19.58 | $61.59 | $0.29 |
| Effect of exchange rate | $0.01 | |||
| Change in cash and equivalents | -$3.87 | -$1.45 | $15.36 | -$2.63 |
News
Fundamentals
| Market cap | $6.55M |
|---|---|
| Enterprise value | N/A |
| Shares outstanding | 5.41M |
| Revenue | $598.00K |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | -$44.95M |
| Revenue Q/Q | N/A |
| Revenue Y/Y | N/A |
| P/E ratio | -0.15 |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | 10.95 |
| P/B ratio | N/A |
| Book/Share | N/A |
| Cash/Share | 0.79 |
| EPS | -$8.31 |
|---|---|
| ROA | -117.52% |
| ROE | N/A |
| Debt/Equity | N/A |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 0.48 |
| Quick ratio | N/A |